In this study we performed a head-to-head comparison of the integrase fC31 derived from a Streptomyces phage and the Sleeping Beauty (SB) transposase, a member of the TC1/mariner superfamily of transposable elements. Mouse liver was cotransfused with a vector containing our most robust human coagulation factor IX expression cassette and the appropriate recombinase recognition site and either a fC31-or a SB transposase-expressing vector. To analyze transgene persistence and to prove somatic integration in vivo we induced cell cycling of mouse hepatocytes and found that the transgene expression levels dropped by only 16 to 21% and 56 to 66% in mice that received fC31 and SB, respectively. Notably, no difference in the toxicity profile was detected in mice treated with either recombinase. Moreover we observed that with the integrase-mediated gene transfer, transgene expression levels were dependent on the remaining noncoding vector sequences, which also integrate into the host genome. Further analyses of a hot spot of integration after fC31-mediated integration revealed small chromosomal deletions at the target site and that the recombination process was not dependent on the orientation in which the fC31 recognition site attached to the pseudo-recognition sites in the host genome. Coupled together with ongoing improvements in both systems this study suggests that both nonviral vector systems will have important roles in achieving stable gene transfer in vivo.
INTRODUCTION
Gene therapy approaches for genetic disorders require longterm and sustained transgene expression levels in vivo. Sustained transgene expression levels were obtained in viral-based and nonviral gene therapy approaches [1] [2] [3] [4] [5] [6] [7] [8] [9] . However, each gene delivery system displays advantages and disadvantages and the ideal gene therapy technology would result in life-long and therapeutic transgene expression levels in vivo without toxicity. Viral gene therapy vectors have been developed and were demonstrated to result in long-term phenotypic correction in mice and larger animal models for hemophilia B [7, [10] [11] [12] . However, major obstacles in viral gene therapy approaches remain. For example the immune response against the incoming viral particle needs to be diminished and the labor-intensive and expensive production of viral vectors is, in contrast to nonviral vectors, a major challenge. Conversely, delivery limitations have diminished the application of nonviral systems. To achieve prolonged transgene expression levels in vivo, nonviral vector systems for somatic integration were developed [5, 6] and cis-acting DNA elements were optimized [13, 14] . It was demonstrated that nonviral-based vectors with the ability to integrate into the host genome maintain stable transgene expression levels even during rapid cell cycling of mouse hepatocytes in vivo [6, 15, 16] .
Two major nonviral vectors for somatic integration currently used in gene therapy approaches are based on the Sleeping Beauty (SB) transposase or the bacteriophage integrase fC31 from Streptomyces. DNA transposons are genetic elements that have the ability to move from one genetic location to another. SB transposase is a molecular reconstruction from the fish genome and belongs to the TC1/mariner family of transposable elements [17] . The SB recombination process is based on a cut-and-paste mechanism and results in integration of the transposon into the chromosomal target site [17, 18] (Fig. 1) . After resurrection of SB it became clear that this transposable element is suitable for somatic gene therapy approaches. It was demonstrated that SB was functional in mammalian cells [19] [20] [21] and shown that this recombinase resulted in persistent transgene expression levels in a mouse model of hemophilia B [5] . Recent data suggest that the target sites of integration after SB-mediated recombination show random genomic distribution and it is estimated that about 35% of transposition events are in genes [22] . This is in sharp contrast to integrating viral vectors such as lentivirus and adeno-associated virus (AAV), which predominantly integrate into active genes [23, 24] .
The bacteriophage integrase fC31 from Streptomyces is a recombinase with the potential to perform site-specific integration into a host chromosome and it was previously demonstrated that hot spots of integration in the mammalian genome exist [6, 25, 26] . In contrast to other bacterial-derived recombinases the phage integrase fC31 is based on a unidirectional reaction in which two fC31 molecules attach to the attB recognition site and the attP pseudo-sites in the mammalian genome (attPV) [27] . The recombination process is based on a 2-bp staggered cut of the DNAs and rotation of the DNA targets by 1808 [27] . The integration reaction results in integration of the transgene flanked by two hybrid att sites, attL and attR (Fig. 1) . After it was demonstrated that the phage integrase fC31 is sufficient to perform site-specific integration in human cells [25, 28] , the in vivo efficacy of this recombinase was tested. It was shown that fC31-mediated integration in mice results in sustained and therapeutic levels of the coagulation factor IX [6] . Another study utilized the fC31 recombinase for correction of inherited human skin diseases [26, 29] .
The goal of this study was to compare directly the in vitro and in vivo efficiency of the two recombinases SB and fC31 in the context of an identical expression cassette. We investigated the stability of transgene expression levels during rapid cell cycling in mouse liver and analyzed the toxicity profile of both recombinases shortly after administration. Recently, we showed that bacterial backbone sequences in nonviral vectors influence transgene expression levels in vivo [30] . Based on these findings we addressed the question if bacterial DNA sequences influence transgene expression levels in a gene therapy approach based on fC31. In contrast to SB-mediated transposition, bacterial backbone sequences integrate into the host genome. Including further ongoing improvements of the SB transposase and the bacteriophage fC31, we believe that both recombinases have great potential for nonviral gene therapy approaches.
RESULTS

A Direct Comparison of the Recombinases fC31 and Sleeping Beauty Transposase in Vitro and in Vivo
In an attempt to compare the integration efficiency in vitro after phage integrase fC31-and SB transposasemediated recombination, we performed a colony-forming assay in HeLa cells. All DNA constructs used for this study are shown in Fig. 2A . Previous studies revealed that the SBmediated integration efficiency in vitro depends on the molar ratios of the SB-encoding plasmid and the transposon due to a recently described overproduction-inhibition effect [41] . To use optimal conditions for SBmediated recombination, we used different molar ratios of the transposase-encoding DNA and the transposon DNA in a colony-forming assay. To ensure that the same amount of total DNA was transfected we added the appropriate amount of bfillerQ DNA to the different groups. In concordance with previous studies [41] this experiment revealed that a transposon-to-transposase ratio of 5:1 resulted in highest transposition efficiency, with a 42-fold increase in colony-forming units compared to groups that received the mutated version of the SB transposase (Fig. 2B) . Further reduction in the amount of SB-encoding DNA by using a transposon-to-transposase ratio of 7.5:1 or 10:1 resulted in similar or slightly lower FIG. 1. Shown schematically is the integration process mediated by the bacteriophage fC31 (INT) and Sleeping Beauty (SB) transposase. Left: Two fC31 molecules attach to the attB recognition site and the attP pseudo-sites in the mammalian genome (attPV) and the substrate with the fC31 attachment site attB attaches to the attP pseudo-sites. The recombination process is based on a 2-bp staggered cut of the DNAs and rotation of the DNA targets by 1808. The integration reaction results in integration of the transgene flanked by two hybrid att sites, attL and attR. Right: SB binds to the inverted repeats (IR) and integrates the transgene by a cut-and-paste mechanism into the host chromosomal DNA. SB cuts the transposon in which the transgene is flanked by the IRs out of the donor plasmid and integrates it into TA dinucleotide base pairs. integration efficiencies, respectively (Fig. 2C ). This result confirms the overproduction-inhibition effect of the transposase protein during SB-mediated integration. Our laboratory recently found that the strength of the promoter driving the expression of SB influences persistence of transgene expression levels in vivo [32] . Thus, we compared the cytomegalovirus (CMV) immediate-early promoter as a strong promoter driving SB expression with the less robust phosphoglycerate kinase promoter (PGK-p) and the elongation factor 1a promoter (EF1a-p). For these groups the transposon-to-transposase ratio was 1:1. This was the same ratio we used for the colony-forming assay, which determined the in vitro efficacy of a fC31-encoding plasmid and the plasmid with the fC31 recognition site. We found that the PGK promoter, the EF1a promoter, and the CMV promoter resulted in a 34-, 17-, and 21-fold increased transposition efficiency, respectively, compared to the inactive mutated SB transposase (mSB) control group (Fig. 2B) . For the fC31-based selection study, we used the substrates pCR-attB-nori and p11, in which the plasmid backbone was deleted. We observed an 18-and 39-fold increase for pCR-attB-nori and pAttB-nori, respectively, compared to groups that received the mutated and inactive version of fC31 (Fig. 2B) . This experiment To determine the integration efficiency the following DNA sequences were transfected into HeLa cells to perform a colony-forming assay. The fC31 (INT) cDNA, mutated fC31 encoding sequence (mINT), SB transposase, and mutated SB transposase (mSB) were driven by the cytomegalovirus immediate-early promoter (CMV-p). Two groups received a SB expression cassette in which the SB cDNA is driven by either the elongation factor a promoter (EF1a-p) or the phosphoglycerate kinase promoter (PGK-p). The integrase fC31 and SB substrates conferring G418-resistant growth contained a neo-resistance gene (neo), the p15 bacterial origin of replication (p15A), the SV40 promoter, and the Tn5 promoter. The recombinase fC31 attachment site attB and the inverted repeats (IR) for SB-mediated recombination were added to the appropriate substrates. (B) In vitro integration efficiency after SB-and fC31-mediated integration. Shown is a summary of counted colonies for each group after methylene blue staining. To use optimized conditions for the SB-mediated integration process transposon-totransposase (Tn:SB) ratios of 1:1, 1:5, and 5:1 were used. Two groups received DNA encoding the active SB cDNA driven by the EF1a promoter or the PGK promoter. All groups received the same amount of total DNA and for a direct comparison of the fC31-and the SB-based recombination system the molar amounts of the appropriate recombinase recognition site-containing plasmid were identical. Experiments were performed in triplicate. (C) Integration efficiencies after SB-mediated integration using Tn:SB ratios of 5:1, 7.5:1, and 10:1.
implies that the plasmid backbone with bacterial DNA sequences that also integrates into the host genome during fC31-mediated integration influences integration efficiency in vitro. In summary we conclude that under optimized conditions the integration efficiencies in vitro for SB and fC31 are similar. SB showed 42-fold increased transposition efficiency above background and fC31 resulted in a 39-fold increase in integration compared to the mutant fC31 control group.
In an attempt to compare the in vivo efficacy of both recombinases, we compared our most robust human coagulation factor IX (hFIX) expression cassette in the context of both the recombinases fC31 and SB. The hFIX expression cassette utilized in this study was described earlier [13, 14] and contained the hFIX cDNA with part of the first intron of the hFIX gene driven by the human a1-antitrypsin promoter (hAAT-p) and two liver-specific enhancers (Fig. 3A) . The in vivo comparison of both recombinases was based on a two-vector approach in which a nonviral vector containing the hFIX expression cassette with the recombinase attachment site was codelivered with a second vector encoding the recombinase fC31 (n = 10 per group) or SB (n = 10 per group). Mouse livers of control groups received a mutated and inactive version of the phage integrase fC31 (mINT; n = 10 per group) and the SB transposase (mSB; n = 10 per group). Although the hFIX expression levels started out at higher levels for the SB group (up to 20,000 ng/ml, normal level 5000 ng/ml), we detected similar serum levels of hFIX 8 weeks postinjection for the fC31 (1867 ng/ml) and the SB group (1489 ng/ml) (Fig. 3B ). To analyze transgene persistence and to prove somatic integration in vivo we induced cell cycling of mouse hepatocytes by performing a surgical two-thirds partial hepatectomy 66 days postinjection. Eighty-four days post-partial hepatectomy we found that the transgene expression levels dropped by 16% (1565 ng/ml) and 66% (498 ng/ml) in mice that received the active fC31 recombinase and the SB transposase, respectively (Figs. 3C and 3D). In contrast to this observation, transgene expression dropped by N96% in both the mINT and the mSB control groups.
FIG. 3.
In vivo properties of the Streptomyces-derived bacteriophage fC31 and the Sleeping Beauty transposase. The in vivo comparison was based on a twovector approach in which the recombinase and the transgene expression cassette with the conferring recombinase attachment site were co-injected. (A) Shown are the DNA sequences transfused into mouse liver. The human coagulation factor IX (hFIX) expression cassette contained the hFIX cDNA and part of the first intron of the hFIX gene driven by the human a1-antitrypsin promoter (hAAT-p) and two liver-specific enhancers. The plasmids pCS-attB-hFIX and pTMCShFIX with the hFIX expression cassette contained the fC31 attachment site attB and the SB inverted repeats (IR), respectively. The fC31 (INT) cDNA, mutated fC31-encoding sequence (mINT), SB transposase, and mutated SB transposase (mSB) were driven by the CMV immediate-early promoter. (B) Vectors were transfused into mouse liver (n = 10 per group, C57Bl/ 6 mice) using a high-pressure tail vein injection method. The plasmids pCS-attB-hFIX (20 Ag) and pTMCS-hFIX (20 Ag) were co-injected with pCMV-INT (20 Ag) or pCMV-mINT (20 Ag) and pCMV-SB (2.0 + 18.0 Ag pBS-P/P) or pCMV-mSB (2.0 + 18.0 Ag pBS-P/ P), respectively. A two-thirds partial hepatectomy was performed 63 days postinjection. Transgene expression levels were monitored at the predicted time points. Means F SD are shown. (C) The relative serum hFIX concentrations for the bacteriophage integrase fC31 and the mutated version of the fC31 recombinase post-partial hepatectomy are shown. (D) The relative transgene expression levels post-partial hepatectomy are shown for the groups that received the plasmids pCMV-SB and pCMV-mSB.
In Vivo Efficacy of Both Recombinases in the Context of the Identical Plasmid Backbone Sequences
Previous data from our laboratory revealed that DNA sequences contained in the plasmid backbone of a nonviral vector can significantly influence the time course and level of transgene expression levels in vivo. Thus, in a further experiment, we compared the in vivo properties of both recombinases when the transgene expression cassettes with the recombinase attachment sites were delivered in the context of an identical plasmid backbone. We co-infused nonviral vectors encoding the recombinases and a second vector with the appropriate recombinase attachment site (Fig. 4A) into the livers of C57Bl/6 mice (n = 10 per group) by high-pressure tail vein injection. Control groups received a vector expressing a mutated version of the bacteriophage integrase fC31 or SB transposase. Expression levels increased and reached peak levels 3 weeks postinjection in all four groups (Fig.  4B) . Interestingly, at this time point, the fC31 group showed highest transgene expression, with serum hFIX concentrations of up to 20,000 ng/ml (Fig. 4B) . In sharp contrast, we observed serum hFIX concentrations of up to 1100, 1300, and 1100 ng/ml for the mutant fC31 group, the SB group, and the mutant SB group, respectively. To investigate the integration efficiency, we induced cell cycling in mouse liver by performing a two-thirds partial hepatectomy (Fig. 3 ) 102 days after vector delivery. One day before partial hepatectomy, we measured serum hFIX levels, and in mice that received the active integrase, we detected serum hFIX concentrations of up to 11,900 ng/ ml (Fig. 4B) . In sharp contrast, in mice injected with the mutated version of the phage integrase fC31 transgene we observed expression levels of up to 290 ng/ml. Mouse livers that were infused with either the SB transposase or the mutated SB recombinase and a hFIX expression cassette flanked by the inverted repeats expressed serum hFIX concentrations of up to 3200 and 649 ng/ml, respectively, 102 days postinjection (Fig. 4B ). After performing a two-thirds surgical hepatectomy we monitored hFIX serum levels for an additional 122 days and, in concordance with the first experiment (Fig. 3) , we found that transgene expression levels dropped only 21% for the bacteriophage fC31-and 54% for the SB transposasetreated animals (Fig. 4C) . Control groups that received the inactive version of either recombinase showed a decrease in hFIX serum concentrations of N95%.
In an attempt to analyze liver samples for hFIXencoding vector genomes, we isolated genomic DNA from mouse liver pre-and post-partial hepatectomy and performed a Southern blot analysis. As illustrated in Fig. 5 , we detected a higher number of vector genomes in mouse liver isolated from animals that received the vector pBSattB-hFIX and the active integrase fC31 compared the mutant fC31 group. Post-partial hepatectomy and in concordance with the hFIX expression levels, we detected vector genomes in the fC31 group but not in the mutant fC31 group (Fig. 5B) . In contrast to this finding, we observed a similar amount of vector genomes in the SB and the mutant SB transposase groups pre-partial hepatectomy (Fig. 5C ). Although hFIX expression could still be detected in mice that received the active SB transposase, 224 days postinjection we detected no vector genomes by the Southern blot performed in this study. However, a more sensitive method might be required to detect the remaining vector genomes in the SB transposase group.
Plasmid Backbone Sequences Influence the in Vivo
Performance of the fC31 Recombinase in a Nonviral Gene Therapy Approach We observed that transgene expression levels after fC31-mediated integration varied among the experiments in which different plasmids were used for the delivery of the attB site and the transgene expression cassette. Thus, in a further step we wanted to address the question of whether bacterial sequences influence the in vivo performance of fC31 in a nonviral gene therapy approach. We injected C57Bl/6 mice (n = 10 per group) with either plasmid pCS-attB-hFIX or plasmid pBS-attB-hFIX (Figs. 3A and 4A) and co-injected with the fC31-encoding vector pCMV-INT or pCMV-mINT, respectively. The bacterial plasmid backbone pCS contains, in addition to the plasmid backbone pBS, an expression cassette encoding the kanamycin resistance gene. We found that 8 weeks postinjection the hFIX expression levels were up to 7.6-fold higher with the pBS backbone compared to the identical expression cassette in the pCS backbone (Fig. 6) . We believe that there are at least two potential explanations for this finding: different plasmid backbone sequences influence the integration efficiency and/or plasmid backbone sequences affect transgene expression levels after fC31-mediated integration into the host genome. Our in vitro study presented in Fig. 2 B suggested that plasmid backbone sequences may influence integration efficiencies after fC31-mediated integration. Taken together these results suggest that the in vitro and in vivo performance of the fC31 integrase is influenced by DNA sequences contained in the plasmid backbone.
Liver Toxicity Studies Revealed No Significant Differences for either the Phage Integrase fC31 or Sb
To analyze the toxicity profile of both recombinases we measured liver enzymes as an indicator of acute toxicity after injection of both fC31 and SB. We detected no significant differences in alanine aminotransferase activity (SGPT) levels in mice treated with either recombinase 1 day after injection (Fig. 7A ). C57Bl/6 mice (n = 10 per group) in all four groups had values that averaged at around 600 U/ml. We believe that these elevated SGPT levels are a consequence of the high-pressure tail vein injection procedure as seen in previous studies [42] . In a further step, we addressed the question if the integrase fC31 alone (Fig. 7B) or co-injected with the appropriate substrate (Fig. 7C ) results in elevated liver enzymes after infusion into mouse liver. The time course revealed that there were no significant differences between the different groups into which the active integrase (INT), the inactive integrase (mINT), or the control plasmid (pBS-P/P) was injected (Fig. 7B) . SGPT levels returned to normal (normal SGPT levels: 10-80 U/ml) 3 days after infusion. In addition we found that there were no significant differences in SGPT levels in mice that received the fC31-encoding plasmid either alone or together with a substrate (Fig. 7C) . Representative histological findings in liver samples obtained from one mouse in each group are shown in Fig. 7D . Liver histology sections revealed that the liver microstructure remained normal in mice that received either recombinase.
Characterization of the Integration Site Mpsl1, a Hot Spot for Phage Integrase fC31-Mediated Integration Recently, the hot spot for fC31-mediated integration in the mouse genome, mpsL1, was published [6] . This finding motivated us to analyze further the integration site mpsL1 in the present study and to test whether the orientation in which the attB site attaches to the mpsL1 site is important. Thus, we performed a PCR that   FIG. 4 . A direct in vivo comparison of the phage integrase fC31 system and the Sleeping Beauty transposase system in the context of the identical bacterial backbone sequences. (A) DNA sequences injected into C57Bl/6 mice. The hFIX expression cassette with the corresponding recombinase recognition site contained in the nonviral vectors pBS-TMCS-hFIX and pBS-attB-hFIX was identical to the one described for Fig. 1A . However, for this experiment both transgene expression cassettes were ligated into the identical plasmid backbone pBluescript (pBS). (B) C57Bl/6 mice (n = 10 per group) were co-injected with either pBS-TMCS-hFIX or pBS-attB-hFIX and the mutated or active version of INT or SB (pCMV-INT or pCMV-mINT and pCMV-SB or pCMV-mSB, respectively). Serum hFIX concentrations were monitored by performing an hFIX ELISA. A two-thirds partial hepatectomy was conducted 102 days after partial hepatectomy for all groups. Means F SD are shown. (C) The relative serum hFIX concentrations 1 day pre-partial hepatectomy compared to the transgene expression levels 16 weeks postpartial hepatectomy are shown.
specifically recognized the mpsL1 integration site for either orientation of the attB site. The strategy of this PCR approach is schematically demonstrated in Fig. 8A and the final PCR product of 280 bp for orientation I (Fig. 8A) is shown in Fig. 8B . A detailed characterization of each integration event at the mpsL1 site is shown in Fig. 8C . In summary, we found deletions of up to 33 and 160 bp in the attB site and the chromosome, respectively (Fig. 8D) . In addition we found insertions into the target chromosome of 6 and 175 bp, of which the 175-bp insertion was derived from the mouse DNA sequence from clone RP23-112C19 on chromosome 11. Sequence analysis of these PCR products, which were received for both primer combinations, strongly suggested that the fC31-mediated recombination process was not dependent on the orientation in which the attB site attaches to the pseudorecognition site in the host genome. This observation is schematically shown in Fig. 8E .
DISCUSSION
At the current time the SB transposase and the phage integrase fC31 are available for nonviral gene therapy approaches that are based on integration of the transgene expression cassette into the host genome. The present study compares directly the in vitro and in vivo properties of the two recombinases fC31 and SB. Under optimized conditions for chromosomal integration SB showed 42-fold increased transposition efficiency above background and fC31 resulted in a 39-fold increase in integration compared to the mutant fC31 control group. This result demonstrates that the in vitro performance of both systems is similar and that both systems will have important roles in achieving stable gene transfer. However, there was a clear difference between the in vitro and in vivo performance for both systems. The SB system seems to work better in vitro than in vivo and the fC31 system supported higher levels of transgene persistence and expression in vivo compared to the SB system. In addition the fC31 system FIG. 5. Southern blot analyses for hFIX-encoding vector genomes in mouse livers that received the fC31 or the SB recombinase. Genomic DNA from mouse liver pre-and post-partial hepatectomy was isolated. Twenty micrograms of liver genomic DNA was digested with the restriction endonuclease HindIII, and a Southern blot was performed, which was hybridized with a hFIX cDNA probe (A). (B) Detection of vector genomes in mouse liver, which received the plasmid pCS-attB-hFIX and the fC31-encoding DNA sequence or a plasmid expressing the mutated fC31 cDNA. (C) Southern blot analyses of mouse liver co-infused with the plasmid pTMCS-hFIX and an expression cassette encoding either the active SB or the inactive mutant SB. seems to perform better in vivo than in vitro. We speculate that fC31-mediated integration might be more efficient in quiescent cells in vivo compared to rapidly dividing cells in vitro. The opposite might be true for SB-mediated integration, which might be more efficient in dividing cells in vitro compared to quiescent cells in vivo. Furthermore, the integration efficiencies of both recombinases may be cell type dependent. In the current study both recombinases were compared only in HeLa cells in vitro and in mouse liver in vivo.
We found that after inducing cell cycling in mouse liver, transgene expression levels dropped by 16 or 21% and 66 or 56% in mice that received the active fC31 recombinase and the SB transposase, respectively. In contrast hFIX expression levels dropped by N96% in both the mutant fC31 and the mutant SB control groups. In concordance with these findings we observed a less pronounced loss of vector genomes in mice that received fC31 compared to the SB group. Taken together these results may indicate that the mechanism of persistence of transgene expression levels during mouse hepatocyte cell cycling is more robust in fC31 approaches compared to SB-based gene therapy approaches. One potential reason for this observation could be a higher integration efficiency in mouse hepatocytes after fC31-mediated recombination compared to SB-mediated integration.
FIG. 7.
Toxicity studies performed after injection of the bacteriophage integrase fC31 and the Sleeping Beauty recombinase. (A) C57Bl/6 mice (n = 10 per group) were injected with the plasmid pCS-attB-hFIX or pTMCS-hFIX and co-injected with either pCMV-INT and pCMV-mINT or pCMV-SB and pCMV-mSB (Fig. 3A) . The average SGPT enzyme levels 24 h postinjection are shown. (B) SGPT levels after transfusion of mouse liver with the active integrase (INT), the inactive integrase (mINT), and the control plasmid (pBS-P/P). (C) SGPT levels in mice that received either the fC31-encoding plasmid alone or together with a substrate. (D) Histopathology of liver after hepatic infusion of either the recombinase fC31 or the SB transposase and the corresponding substrate. Representative histological findings in liver samples were obtained from one mouse in each group. Hematoxylin and eosin staining of formalin-fixed liver sections from mice co-injected with pCS-attB-hFIX and pCMV-INT or pCMV-mINT or co-injected with pTMCS-hFIX and pCMV-SB or pCMV-mSB are shown. Original magnification: Â20.
FIG. 8.
Characterization at the hot spot of integration after fC31-mediated recombination. To characterize the chromosomal effects we used a PCR strategy that specifically detects the previously described integration site in mouse liver mpsL1. (A) Schematically shown is the PCR approach to test whether the orientation (primer combination I and II) in which the attB site attaches to the mpsL1 (PV) integration site is important. The primer attB-F and the nested primer attB-F3 bind in the attB site and the primers MpsL1 forw and MpsL1 rev bind on the opposite sites of the target site mpsL1 (PVarm). Primers are indicated by arrows. (B) The final PCR products of which the sequences were analyzed. Shown is an example of the primer combination attB and MpsL1 forw for the first PCR and attB-F3 and MpsL1 forw for the second PCR (primer combination I). A similar PCR was performed for the primer combination attB and MpsL1 rev and the second PCR was performed with the primers attB-F3 and MpsL1 rev. Studies in which marker genes are used to determine and quantify the integration efficiency in vivo for both recombinases may shed light on that question. It is also possible that the relative integration efficiencies in vivo are similar for the SB and the fC31 system but transgenes delivered by the fC31 system display a better expression profile. Another potential explanation for the more robust transgene expression levels observed with fC31 may be the duration and amount of the fC31-expressing vector DNA in mouse hepatocytes. We injected 10-fold more DNA of the fC31-encoding vector compared to the SB-expressing vector because in contrast to SB [41] fC31 appears to have no overproduction-inhibition effect. Thus, the amount of DNA molecules expressing fC31 is most likely significantly higher than the number of SBencoding vector molecules, which might increase the integration efficiency and thus transgene expression levels in vivo. In the present study we induced cell cycling in mouse liver 2 to 3 months postinjection. During the time prior to induction of cell cycle, episomal DNA most likely persists in quiescent cells. Previous studies showed that up to 10 copies per hepatocyte are still present 10 weeks postinjection [16] . Finally, it needs to be analyzed if transgenes delivered by the fC31 system have a more robust mechanism to persist extrachromosomally compared to transgenes that were introduced into mouse hepatocytes by the SB system.
We found microdeletions of up to 160 bp after fC31-mediated integration at the attB site and the previously published chromosomal hot spot of integration in mouse liver, mpsL1 [6] . In concordance with our investigation microdeletions in the attB arm of the integration site were also detected in a previous in vitro study [25] . In sharp contrast to this phenomenon, chromosomal deletions after SB-mediated integration are rare. Characterization of chromosomal integration sites of naturally integrating viral vectors, such as AAV, revealed that deletions of even larger than 200 bp can occur [23, 43] . However, the PCR strategy used in our study to characterize the integration sites is able to pick up deletions and/or insertions of only up to~200 bp. A more thorough study that characterizes the integration sites after fC31-mediated integration in detail will address the question if larger deletions at the chromosomal target site occur.
This study suggested that the in vivo performance after fC31-mediated integration may be dependent on the remaining plasmid backbone sequences, which, in addition to the transgene expression cassette, ultimately integrate into the host genome (Fig. 5) . We speculate that there are several potential explanations for this finding. (1) DNA sequences contained in the plasmid backbone influence the fC31-mediated integration efficiency and/or (2) plasmid backbone sequences influence transgene expression levels after integration of the transgene into the host genome and/or (3) plasmid backbone sequences play a role in transgene persistence and duration of transgene expression from episomal vector DNA. Our in vitro study presented in Fig. 2B suggested that plasmid backbone sequences may indeed play an important role in integration efficiency. The colony-forming assay revealed a twofold increase in G418-resistant colonies if the plasmid backbone was completely deleted from the circular substrate for fC31-mediated integration. Previous studies demonstrated that bacterial backbone sequences have the potential to influence significantly the duration of transgene expression levels in a nonviral gene therapy approach [30, 44] . There is strong evidence that bacterial DNA sequences in a nonviral vector may play a role in episomal transgene silencing [30] . We propose that integrated bacterial sequences may be involved in silencing of the transgene expression cassette or may function as insulators. In addition low-level leaky expression of bacterial DNA-encoded transcripts may occur, which may interfere with the transcriptional products of the transgene expression cassette. To improve further nonviral integrating vectors based on fC31 it may be of interest to generate a vector devoid of all bacterial sequences. Recent studies utilizing episomal minicircles that are devoid of bacterial sequences result in significantly increased transgene expression levels compared to nonviral vectors that still contain bacterial DNA backbone sequences [45] .
The current study may indicate that a gene therapy approach in vivo based on fC31 may be superior to a gene therapy protocol that utilizes the wild-type SB transposase. However, based on our in vitro study and recent publications [32, 41, 46] it is extremely important to point out that recent developments in the transposon technology may dramatically improve gene therapy approaches based on this type of recombinase. Recently, a hyperactive SB transposase was developed. Mutational analyses of the N-terminal DNA binding domain revealed hyperactive mutants with about a sixfold increased activity in vivo [46] . Thus, a direct comparison of the hyperactive SB and the fC31 recombinase would be of great interest. Moreover it was recently demonstrated that the promoter strength strongly influences transposition efficiencies in vivo [32] . In addition, more safety issues for fC31-mediated recombination in mammalian cells need be addressed. Careful studies about target site selection of fC31 and other members of this recombinase family need to be performed and a detailed characterization of integration sites in mammalian cells needs to be undertaken. Taken together with ongoing improvements in both systems including the recent development of transposase hypermutants, this study suggests that both nonviral vector systems will have an important role in achieving stable gene transfer in vivo but can be improved further with optimization.
MATERIALS AND METHODS
DNA constructs. The plasmid pBS-ApoEHCR-hAATp-FIX-Int-bpA, containing the hFIX expression cassette in which a hFIX minigene is driven by the hAAT-p and two liver-specific enhancers, was previously described [13, 14] . The plasmids pCR-attB (pTA-attB) [6, 28] and pT-MCS [5] were described elsewhere. The SpeI fragment from pBS-ApoEHCR-hAATp-FIXInt-bpA containing the hFIX expression cassette was cloned into either the SpeI site of pCR-attB or the SpeI site of pT-MCS, resulting in pCR-attBhFIX and pT-MCS-hFIX, respectively. The EcoRI fragment from pCR-attB with the 308-bp fC31 recognition site was subcloned into the EcoRI site of pBluescript K/S (pBS K/S; Stratagene) followed by ligation of the SpeI fragment from pBS-ApoEHCR-hAATp-FIX-Int-bpA containing the hFIX expression cassette blunt-ended into the EcoRV site, resulting in pBS-attBhFIX. The KpnI-XbaI fragment obtained from pT-MCS with the inverted repeats (IRs) was subcloned into the EcoRV site of pBS S/K by blunt-end ligation, resulting in pBS-TMCS. The SpeI fragment containing the DNA sequences for the hFIX expression cassette was cloned blunt into the NsiI and NotI sites of pBS-TMCS, resulting in pBS-TMCS-hFIX.
The plasmids pCR-attB-nori and pTMCS-Snori were used to determine the integration efficiency in vitro by performing a colony-forming assay. To produce the plasmid pCR-attB-nori the BsmI fragment from pAAVSnori [31] with the selection marker and the p15 bacterial origin of replication was cloned blunt into the EcoRV site of pCR-attB. The plasmid p11, which is deleted for the plasmid backbone, was based on pCR-attBnori and was generated by digesting pCR-attB-nori with SpeI and NotI followed by a fill-in reaction to create blunt ends and religation. The plasmid pTnori [5] was previously described and contained the identical selection marker flanked by the SB IRs.
The plasmid pThAAT.PGK.SB.uni was described previously [32] and contains an expression cassette for SB10 in which SB cDNA is driven by the PGK promoter. The plasmid pHM5.lox.EF1a.SB10 encoding SB10 under the transcriptional control of the EF1a-p is based on the previously described vector pHM5 [33, 34] . The plasmids pCMV-SB, expressing the SB transposase from the CMV immediate-early promoter, and pCMV-mSB expressing an inactive version of the SB transposase, into which an aspartate Y alanine (D244A) mutation was introduced into the catalytic D,D(35)E domain, have been described [5] . The fC31 integrase expression plasmid pCMV-INT, in which the fC31 cDNA is driven by the CMV promoter, has been used in a previous study [28] . The plasmid pCMV-mINT, expressing an inactive version of the integrase fC31, was a gracious gift from Michele P. Calos. This mutated version of the phage integrase fC31, which contains an S12F mutation, was described earlier [35] .
In vitro studies. HeLa cells were cultured in DMEM supplemented with 10% fetal bovine serum, 100 units/ml penicillin-streptomycin, and 20 mM l-glutamine. To perform a colony-forming assay cells were seeded in 6-cm dishes and, at 50 to 80% confluency, transfected with the plasmid DNA using Superfect (Gibco BRL). For all in vitro studies, the same amount of total DNA was transfected and as bfillerQ DNA the plasmid pBS-P/P [2] was used. The molar ratios of the recombinase-encoding plasmid and a second plasmid with the recombinase recognition site were 1:1 for fC31 and 1:1, 1:5, and 5:1 (transposon-to-transposase ratio) for the SB transposase. The transposon-to-transposase ratio for groups that received a plasmid in which SB is driven by the PGK promoter or the EF1a promoter was 1:1. For a direct comparison of the fC31-and the SB-mediated integration efficiencies the same molar amounts of the appropriate recombinase attachment site were transfected. We transfected 1 Ag of the plasmid pTnori per 6-cm dish and the molar amounts of recombinaseencoding DNA and plasmids with the recombinase attachment sites in other groups were adjusted accordingly. Forty-eight hours after transfection cells were split into 10-cm dishes at two different densities (3.8 Â 10 4 and 3.8 Â 10 5 cells/10-cm dish). After 14 days of G418 selection (500 mg/ml) colonies were stained with methylene blue and counted.
Animal procedures. C57Bl/6 mice (ca. 8 weeks of age) were injected via high-pressure tail vein injection as previously described [36, 37] . In brief, the plasmid DNA was diluted in 2.0 ml of a physiological 0.9% (w/v) NaCl solution and injected into the mouse tail vein over a period of 5-7 s. The plasmids pCS-attB-hFIX or pBS-attB-hFIX (20 Ag) and pTMCShFIX or pBS-TMCS-hFIX (20 Ag) were co-injected with pCMV-INT (20 Ag) or pCMV-mINT (20 Ag) and pCMV-SB (2.0 + 18.0 Ag pBS-P/P [2] ) or pCMV-mSB (2.0 + 18.0 Ag pBS-P/P), respectively. To obtain serum samples blood was collected by retro-orbital technique at the predicted time points. Surgical two-thirds partial hepatectomies were performed as described earlier [38] .
Blood analyses. Mouse serum human FIX antigen levels were determined by an enzyme-linked immunosorbent assay (ELISA) as previously described [2, 13] . The normal human serum level was 5000 ng/ml. SGPT assays were performed by using a diagnostic kit for colorimetric determination of SGPT (TECO Diagnostics, Anaheim, CA, USA; Cat. No. A526-120).
Southern blot analysis. Genomic DNA from mouse liver was isolated by using a previously described protocol [39] . In brief about 100 mg of mouse liver was harvested and digested overnight with proteinase K. Genomic DNA was extracted by a previously described salting-out procedure followed by an ethanol precipitation. Twenty micrograms of genomic mouse liver DNA was digested with the restriction enzyme nuclease HindIII, run on a 0.8% agarose gel, and electrotransferred to a Hybond membrane (Amersham). The blots were hybridized with an [a-
32 P]dCTPlabeled cDNA hFIX probe (HindIII/EcoRI fragment from pAAVCM2), using a random priming kit (Stratagene).
Detection and characterization of the mpsL1 integration sites in mouse liver. Genomic DNA from mouse liver was isolated and a PCR with the two mpsL1 integration site-specific primers, MpsL1 forward (5V-GTGGCA-CATTCCTTAATCCC-3V) and MpsL1 reverse (5V-TGAGGAGGAGCCTTAG-CAAC-3V), which were combined with the attB-specific primer AttB-F (5V-TACCGTCGACGATGTAGGTCACGGTC-3V), was performed. This PCR was followed by a second PCR in which the primer attB-F3 (5V-CGAAGCCGCGGTGCG-3V) was combined with either MpsL1 forward or MpsL1 reverse. To determine the DNA sequences of the resulting PCR products the DNA fragments were subcloned using a TA cloning kit (Invitrogen) and sequenced.
Histology procedures. Liver sections were generated as described earlier [40] . In brief, mouse liver was fixed in 10% paraformaldehyde and embedded in paraffin. Tissue sections were generated and hematoxylin and eosin staining was performed.
